Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lu, Renquan ^a,b   Sun, Min ^a,b   Feng, Jingjing ^a,b   Gao, Xiang ^a,b   Guo, Lin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Myofibrillogenesis regulator 1ovarian cancerproliferationinvasion

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; MESSENGER RNA; MYOFIBRILLOGENESIS REGULATOR 1 PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; MUSCLE PROTEIN; NEUTRALIZING ANTIBODY; PNKD PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL KINETICS; CELL SPREADING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MYOFIBRILLOGENESIS REGULATOR 1 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; TUMOR GENE; WESTERN BLOTTING; APOPTOSIS; CELL MOTION; CELL STRAIN HEK293; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; ANTIBODIES, NEUTRALIZING; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MIDDLE AGED; MUSCLE PROTEINS; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79959391005     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-270     Document Type: Article

References (16)

1. American Cancer Society Cancer Facts & Figures 2009. 2009, 4. Atlanta: American Cancer Society, American Cancer Society.
2. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010, 3:7. 10.1186/1756-8722-3-7, 2831814, 20146807.
3. Fazal F, Gu LZ, Ihnatovych I, Han YJ, Hu WY, Antic N, Carreira F, Blomquist JF, Hope TJ, Ucker DS, Lanerolle PD. Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. Mol Cell Biol 2005, 25:6259-6266. 10.1128/MCB.25.14.6259-6266.2005, 1168802, 15988034.
4. Roovers K, Assoian RK. Effects of Rho kinase and actin stress fibers on sustained extracellular signal-regulated kinase activity and activation of G (1) phase cyclin-dependent kinases. Mol Cell Biol 2003, 23:4283-4294. 10.1128/MCB.23.12.4283-4294.2003, 156148, 12773570.
5. Gutjahr MC, Rossy J, sNiggli V. Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. Exp Cell Res 2005, 308:422-438. 10.1016/j.yexcr.2005.05.001, 15950966.
6. Ren KH, Jin HX, Bian CJ, He HW, Liu X, Zhang SH, Wang YG, Shao RG. MR-1 modulates proliferation and migration of human hepatoma HEPG2 cells through MLC2/FAK/AKT signaling pathway. J Bio Chem 2008, 283:35598-35605.
7. Li TB, Liu XH, Feng S, Hu Y, Yang WX, Han Y, Wang YG, Gong LM. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle. Acta Biochimica et Biophysica Sinica 2004, 36:405-411. 10.1093/abbs/36.6.405, 15188055.
8. Rainier S, Thomas D, Tokarz D, Ming L, Bui M, Plein E, Zhao X, Lemons R, Albin R, Delaney C, Alvarado D, Fink JK. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonia choreoathetosis. Arch Neurol 2004, 61:1025-1029. 10.1001/archneur.61.7.1025, 15262732.
9. Ghezzi D, Viscomi C, Ferlini A, Gualandi F, Mereghetti P, DeGrandis D, Zeviani M. Paroxysmal non-kinesigenic dyskinesia is caused by mutations of the MR-1 mitochondrial targeting sequence. Human Molecular Genetics 2009, 18:1058-1064. 10.1093/hmg/ddn441, 19124534.
10. Chen DH, Matsushita M, Rainier S, Meaney B, Tisch L, Feleke A, Wolff J, Lipe H, Fink J, Bird TD, Raskind WH. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia. Arch Neurol 2005, 62:597-600. 10.1001/archneur.62.4.597, 15824259.
11. Li HL, She ZG, Li TB, Wang AB, Yang QL, Wei YS, Wang YG, Liu DP. Overexpression of Myofibrillogenesis Regulator-1 Aggravates Cardiac Hypertrophy Induced by Angiotensin II in Mice. Hypertension 2007, 49:1399-1408. 10.1161/HYPERTENSIONAHA.106.085399, 17420335.
12. Clemens MJ, Bushel LM, Jeffrey IW, Pain VM, Morley SJ. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 2000, 7:603-615. 10.1038/sj.cdd.4400695, 10889505.
13. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 2001, New York: Cold Spring Harbor Laboratory Press, 3.
14. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005, 96:379-386. 10.1111/j.1349-7006.2005.00062.x, 16053508.
15. Lu RQ, Guo L, Hu J. Studies on the value of human epididymis protein 4 in patients with ovarian cancer. Ch J Clin Lab 2009, 32:1379-1383.
16. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, Parkin D, Murray GI. Cytochrome P450 over-expression in primary and metastatic ovarian cancer. Br J Cancer 2001, 85:242-246. 10.1054/bjoc.2001.1907, 2364045, 11461084.